Why the study?
Circulating ketone bodies may provide incremental information beyond established biomarkers, and a multi-marker risk score could improve risk stratification for incident heart failure in individuals without cardiovascular disease.
Does the addition of ketone bodies to NT-proBNP and hs-cTnT improve the prediction of incident heart failure in participants without cardiovascular disease?
Does the addition of ketone bodies to NT-proBNP and hs-cTnT improve the prediction of incident heart failure in participants without cardiovascular disease?
Answers are grounded in this paper and cite their sources.
The addition of circulating ketone bodies to established biomarkers (NT-proBNP and hs-cTnT) significantly improves the prediction of incident heart failure in individuals without baseline cardiovascular disease.
AIMS: Circulating ketone bodies (KB) have emerged as a potential adjunctive biomarker for incident heart failure (HF) risk and might provide incremental information beyond established biomarkers. A multi-marker risk score may improve risk stratification of incident HF in the community. The authors aim to develop a risk score using N-terminal proB-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin (hs-cTnT) and a unique systemic biomarker of KB to predict HF among participants without cardiovascular disease. METHODS AND RESULTS: A multi-marker score was developed incorporating NT-proBNP ≥ 125 pg/mL, hs-cTnT ≥ 14 ng/L, and total KB ≥ 75th percentile (316 μmol/L), with one point allocated for each abnormal marker among Multi-Ethnic Study of Atherosclerosis participants. Multivariable Cox model was used to assess the association between multi-marker risk score and the risk of incident HF. Among 6748 participants, there were 383 incident HF events over a median follow-up of 15.7 years. The three biomarkers exhibited poor correlation with one another (r < 0.06 for all). The addition of KB to NT-proBNP and hs-cTnT to identify incident HF improved 5- and 10-year risk prediction (C-statistic 0.74 vs. 0.77, P = 0.02 and 0.70 vs. 0.73, P = 0.02, respectively). There was no evidence of miscalibration using the multi-marker score for predicting 5- and 10-year HF risk (P > 0.05). A graded association was observed between the multi-marker score and risk of HF independent of established clinical factors. CONCLUSION: The addition of plasma KB to a clinical risk score using biomarkers of cardiac injury and stress may further improve the prediction of incident HF.
No takes yet. Share an insight, caveat, or question.
Chevli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: